オプションチェーンは、Outset Medicalの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Outset Medicalの市場センチメントを評価します。.

Outset Medical (NASDAQ:OM) 株価情報, オプションチェーン

Outset Medical

Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.

Outset Medical Inc

MANTRA DAO

Grupo Aeroportuario del Centro Norte S.A.B. de C.V. - American Depositary Shares each representing 8 Series B shares

Grupo Aeroportuario del Centro Norte SAB de CV

Omagine Inc

Tidal Trust III VistaShares Target 15 Berkshire Select Income ETF

Origin Protocol - United States Dollar

Omnicom Group Inc

Old Market Capital Corporation - Common Stock

Old Market Capital Corp

Omnicell Inc

Omada Health Inc

ORMAND INDUSTRIES INC by Ormand Industries, Inc.

Ormand Inds Inc

Omeros Corp

Odyssey Marine Exploration, Inc. - Common Stock

Odyssey Marine Exploration Inc

OneMain Holdings Inc

Invesco Exchange-Traded Self-Indexed Fund Trust Invesco Russell 1000 Dynamic Multifactor ETF

Invesco Exchange-Traded Self-Indexed Fund Trust Invesco Russell 2000 Dynamic Multifactor ETF

OmiseGO - United States Dollar

OMEGA THERAPEUTICS INC by Omega Therapeutics, Inc.

Omega Therapeutics Inc

OMAI GOLD MINES CORP by OMAI GOLD MINES CORP.

Omai Gold Mines Corp

OMEGA OIL NL by OMEGA OIL NL

OMEGA PAC RES INC by Omega Pacific Resources Inc.

Omega Pacific Resources Inc

Ohmyhome Ltd

Omni Health Inc

OM HOLDINGS INTL INC by OM Holdings International, Inc.

Om Holdings International Inc

OM Holdings Ltd

Owens & Minor Inc

Singular Genomic Systems Inc COM NEW

Omid Holdings Inc

oOh media Ltd

OMNIMMUNE HOLDINGS INC by Omnimmune Holdings, Inc.

Omnimmune Holdings Inc

OMINECA MINING & MTLS ORD by Omineca Mining & Metals Ltd.

Omineca Mining and Metals Ltd

OMN - United States Dollar

Omni Network - United States Dollar

Omphalos Corp

OMNIQ Corp

OMRON Corp

Orthometrix Inc

OMS Energy Technologies Inc. - Ordinary Shares

OMS Energy Technologies Inc

OMNITEK ENGINEERING CORP by Omnitek Engineering Corp.

OmniTek Engineering Corp

Omni Ventures Inc

OMV AG

Omnia Wellness Inc

Osisko Metals Inc

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) shares soared to a new all-time high Monday morning, driven by investor enthusiasm following CEO Mark Zuckerberg&#8217;s ambitious plans to restructure the company&#8217;s artificial intelligence division. The move signals a deep commitment to developing &#8220;superintelligence,&#8221; advanced AI systems capable of outperforming humans.
What To Know: Per a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-06-30/zuckerberg-announces-meta-superintelligence-effort-more-hires">report</a>, this strategic pivot includes the formation of Meta Superintelligence Labs, which will be spearheaded by Alexandr Wang, the former CEO of the data-labeling startup Scale AI. 
Meta&#8217;s focus on AI has been further solidified by a recent <a href="https://www.benzinga.com/markets/tech/25/06/46141985/metas-play-for-voice-ai-could-shake-up-the-competition">$14.3 billion investment</a> in Scale AI and the recruitment of top talent from rivals such as OpenAI and Google. These aggressive steps into the AI landscape have bolstered investor confidence in Meta&#8217;s future growth potential.
The company&#8217;s recent significant investments in <a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth">renewable energy</a> to power its energy-intensive AI data centers have also been well-received. This comprehensive strategy, combining cutting-edge AI development with sustainable operational goals, has propelled Meta&#8217;s share price to record highs in 2025.
Analyst Ratings: Driven in part by the company&#8217;s standout <a href="https://www.benzinga.com/news/earnings/25/04/45117948/meta-q1-earnings-eps-beat-revenue-up-16-ai-approaches-1-billion-monthly-actives-capital-expenditures-forecast-raised">first-quarter</a> financial results in April, Wall Street <a href="https://www.benzinga.com/quote/META/analyst-ratings">analysts</a> have echoed the bullish sentiment, with several firms reiterating positive ratings and raising their price targets for Meta. 
In the last week of June alone, Piper Sandler reiterated its Overweight rating while significantly lifting its price target to $808. Similarly, UBS and Citigroup maintained their Buy ratings, increasing their price targets to $812 and $803, respectively. 
This wave of upward revisions from major financial institutions reflects a strong consensus that Meta&#8217;s strategic initiatives, particularly in artificial intelligence, will continue to drive significant value for shareholders.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, META shares are trading marginally higher by 0.36% to $736.29 Monday afternoon. The stock has a 52-week high of $747.90 and a 52-week low of $442.65. META stock is also higher by some 25% in the second quarter of 2025.
Read Also: <a href="https://www.benzinga.com/news/entertainment/25/06/46122235/mark-zuckerberg-hated-the-social-network-film-dont-tell-him-a-sequel-is-coming">Mark Zuckerberg Hated &#8216;The Social Network&#8217; Film: Don&#8217;t Tell Him A Sequel Is Coming</a>
<h2 class="wp-block-heading">How To Buy META Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Meta Platforms&#8217; case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

News

Meta Pursues 'Superintelligence' With New OpenAI Hires, Stock Climbs To Fresh Highs

BIMA, a decentralized finance (DeFi) platform focused on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-backed stablecoins, announced on Monday the launch of real-yield vaults for its USBD stablecoin in collaboration with Bracket, a DeFi strategy provider supported by Binance Labs.
The partnership will allow BIMA users to access on-chain yield strategies without selling its Bitcoin.
Bracket's infrastructure will power these vaults, offering secure, policy-managed smart contracts, institutional-grade accounting, and verified net asset value reporting.
USBD is a Bitcoin-backed stablecoin that is over-collateralized by Bitcoin derivatives and offers a capital-efficient structure. Unlike traditional stablecoins such as USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) or USDT (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>), USBD is designed to support multiple yield strategies within the crypto ecosystem. 
Users can either deposit Bitcoin or stake BTC to mint USBD, using liquid staking tokens as collateral.
Bracket's system will provide the backend for BIMA's yield vaults, enabling the integration of institutional-grade yield opportunities directly within BIMA's ecosystem. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46173137/the-investment-rule-ric-edelman-just-threw-out-and-what-he-replaced-it-with">The Investment Rule Ric Edelman Just Threw Out—And What He Replaced It With</a>
This setup is aimed at Bitcoin holders seeking yield without liquidating their positions.
Sid Sridhar, founder and CEO of BIMA, said the partnership is intended to provide Bitcoin holders with access to yield strategies that do not require exiting Bitcoin exposure.
Mike Wasyl, co-founder and CEO of Bracket, said the collaboration will deliver scalable yield solutions for Bitcoin-native users.
BIMA's recent mainnet launch introduced over-collateralization safeguards, a stability pool to manage under-collateralized positions, and wallet integrations with platforms such as Ledger, MetaMask and XVerse.
These features enable users to mint USBD through a step-by-step process while maintaining direct Bitcoin exposure.
The vault system is intended to make yield-generating strategies available to both institutional and retail participants, offering a range of risk profiles from conservative to growth-oriented.
Read Next: • <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46169668/barclays-faces-epstein-fallout-as-former-ceo-faces-trial">Barclays Faces Epstein Fallout As Former CEO Faces Trial</a>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$USDC

$USDT

New Bitcoin-Backed Stablecoin Vaults Offer Yield Strategies Without Requiring BTC Sales

<a href="https://www.bloomberg.com/news/articles/2025-06-30/apple-weighs-replacing-siri-s-ai-llms-with-anthropic-claude-or-openai-chatgpt">https://www.bloomberg.com/news/articles/2025-06-30/apple-weighs-replacing-siri-s-ai-llms-with-anthropic-claude-or-openai-chatgpt</a>

General

AAPL

MSFT

'Apple Weighs Using Anthropic or OpenAI to Power Siri in Major Reversal'- Bloomberg

At Applied Digital's Ellendale, North Dakota campus, BASX is deploying bespoke free cooling chillers — optimized for cold-climate operation, reducing power demand, and requiring zero water consumption
REDMOND, Ore., June 30, 2025 /PRNewswire/ --&nbsp;BASX, a leader in advanced cooling and custom solutions for data centers and mission-critical environments, and a wholly owned subsidiary of AAON, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>), a leading provider of high-performance, energy-efficient HVAC solutions, today announced a partnership with Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) ("Applied Digital"). Applied Digital, a designer, builder, and operator of next-generation digital infrastructure designed for High-Performance Computing (HPC) applications.
As part of the collaboration, BASX designed and manufactured a customized free cooling chiller system for Applied Digital's AI factory in Ellendale, North Dakota, known as Polaris Forge 1. The system is purpose-built to meet the performance demands of AI infrastructure in a cold climate, while maximizing energy efficiency and sustainability.

AAON

APLD

AAON's BASX Partners With Applied Digital For Next-Gen High-Performance Computing Applications

Leerink Partners analyst Jonathan Chang maintains Zai Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) with a Outperform and raises the price target from $73 to $75.

Price Target

Analyst Ratings

ZLAB

Leerink Partners Maintains Outperform on Zai Lab, Raises Price Target to $75

Reuters Cites Court Ruling Saying Apple Must Face US Antitrust Lawsuit Accusing It Of Monopolizing Smartphone Market

<a href="https://asia.nikkei.com/Business/Automobiles/Honda-delays-cuts-target-for-Japan-fuel-cell-production-plans">https://asia.nikkei.com/Business/Automobiles/Honda-delays-cuts-target-for-Japan-fuel-cell-production-plans</a>

'Honda delays, cuts target for Japan fuel cell production plans'- Nikkei Asia

SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares are up 7% on Monday, adding to strong gains over the past three months. As the second quarter comes to a close, here&#8217;s a look at key highlights from the period.
What Happened: SoundHound shares are on pace to close out the second quarter up approximately 30%. Recent analyst coverage suggest the stock may have more room to run.
Piper Sandler initiated coverage in late May with a price target of $12 and Wedbush and HC Wainwright maintained Outperform and Buy ratings last month with price targets of $15 and $18, respectively.
SoundHound has a strong momentum score of 90.62, according to <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjliKyC25mOAxVaD1kFHc8zL8IQFnoECCMQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>. For more trend information sign up for Pro or check out Benzinga&#8217;s rankings tools on <a href="https://www.benzinga.com/quote/SOUN">SoundHound AI Stock Price, Quotes and Forecasts</a>.
SoundHound reported first-quarter results last month, showing 151% growth despite narrowly missing revenue estimates.
The company guided for full-year revenue of $157 million to $177 million, versus analyst estimates of $166.17 million.
&#8220;SoundHound continues to extend its reach and create new possibilities for real world AI applications. The release of our complete AI agent platform delivers full, voice-enabled Agentic AI for customers across all industries,&#8221; the company said in its first-quarter earnings release.
SoundHound is due to report second-quarter results in early August, although a date has not yet been set by the company. Analysts expect a loss of 9 cents per share on quarterly revenue of $32.88 million. The company had consistently beat estimates for several quarters before missing revenue expectations in its most recent report.
Related Link: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46176358/cava-stock-has-fallen-over-the-past-three-months-whats-going-on">Cava Stock Has Fallen Over The Past Three Months: What&#8217;s Going On?</a>
SOUN Price Action: At the time of writing, SoundHound stock is trading 8.85% higher at $10.70, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjliKyC25mOAxVaD1kFHc8zL8IQFnoECCMQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image via Shutterstock

Movers

SOUN

SoundHound Stock Has Risen Over The Past Three Months: What's Going On?

Telsey Advisory Group analyst Joseph Feldman maintains Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Outperform and maintains $455 price target.

Telsey Advisory Group Maintains Outperform on Home Depot, Maintains $455 Price Target

WIIM

METC

Ramaco Resources shares are trading higher after the company announced it will release updated information regarding its Brook mine rare earth and critical minerals project on July 1st.

INDV

Indivior shares are trading higher after the company was added to the Russell 2000 index. Additionally, Craig-Hallum raised its price target on the stock from $15 to $22.

H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>), highlighting the company&#8217;s &#8220;rebirth&#8221; following the in-licensing of telitacicept.
On Thursday, the company announced a strategic licensing agreement and a major capital raise to support its <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46120176/why-this-biotech-stock-just-doubled-in-a-single-day" rel="noreferrer noopener">push into autoimmune therapies</a>.
Vor Bio signed an exclusive global licensing deal with RemeGen Co., Ltd., giving it rights outside Greater China to develop and commercialize telitacicept, a dual-action fusion protein already approved in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46108474/puretech-founded-entity-vor-bio-announces-exclusive-global-license-agreement-with-remegen-for-late" rel="noreferrer noopener">China for multiple autoimmune disorders</a>.
Also Read: <a href="https://www.benzinga.com//node/46120176">Why This Biotech Stock Just Doubled In A Single Day</a>
Under the agreement, Vor will pay $125 million upfront, $45 million in cash, $80 million in stock warrants, and potential milestone payments exceeding $4 billion and tiered royalties.
The company also announced that Jean-Paul Kress has stepped in as CEO and Chairman, replacing Dr. Robert Ang, who will stay on as a strategic advisor through October.
Commenting on the development, HC Wainwright stated, &#8220;Overall, we are encouraged by the quick resurrection of the company by the board and the management as this transaction brings a de-risked asset that could be commercialized in the US starting mid-2028.&#8221;
Analyst Swayampakula Ramakanth upgraded Vor Biopharma from Neutral to Buy on Monday with a <a target="_blank" href="https://www.benzinga.com/quote/VOR/analyst-ratings" rel="noreferrer noopener">price forecast of $3</a>.
Ramakanth highlights the significant market opportunity for telitacicept in generalized myasthenia gravis (gMG). Based on a 2018 survey of Medicare data, an estimated 82,700 people in the U.S. had gMG in 2021, with approximately 75% receiving treatment.
The analyst projects that if telitacicept is priced at $225,000 per patient yearly and captures 15% of the U.S. market, peak annual sales could reach $1.8 billion.
Furthermore, the analyst says, should the drug successfully launch in the EU and Japan, with commercial partners managing sales outside the U.S. and achieving a 10% market share, it could generate an additional $2.7 billion in combined sales and royalties.
While RemeGen is conducting a Phase 3 trial of telitacicept for lupus (SLE) in the U.S. and EU, the analyst notes that Vor Biopharma currently lacks a defined strategy for marketing the drug for SLE. Consequently, any potential sales from this indication are not factored into Vor&#8217;s current projections.
Price Action: VOR stock is up 49.1% at $1.58 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/46165307/us-credit-rating-would-fall-if-trumps-big-beautiful-bill-is-approved-says-thomas-massie-heres-what-it-means-for-americans" target="_blank" rel="noreferrer noopener">US Credit Rating Would Fall If Trump&#8217;s Big Beautiful Bill Is Approved, Says Thomas Massie: Here&#8217;s What It Means For Americans</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Upgrades

Health Care

Trading Ideas

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

TROX

Tronox Holdings shares are trading lower after BMO Capital downgraded the stock from Market Perform to Underperform and cut its price target from $7 to $3.

Leonardo DRS shares are trading higher after Goldman Sachs initiated coverage on the stock with a Buy rating and announced a price target of $49.

Wall Street veteran and Fundstrat co-founder Tom Lee is set to bring Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) into the spotlight, with plans to position BitMine Immersion Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) as the &#8216;<a href="https://www.benzinga.com/crypto/25/06/46089976/tom-lee-says-microstrategy-could-outpace-bitcoin-gains-goes-up-a-lot-more-as-btc-rallies">MicroStrategy of Ethereum.</a>&#8216;
What Happened: In an CNBC Squawk <a href="https://www.cnbc.com/video/2025/06/30/fundstrats-tom-lee-on-being-named-chairman-of-bitmine-immersion-technologies.html">interview</a> on June 30, Lee announced his new role as chairman of BitMine, a small-cap Bitcoin mining firm valued at $26 million. 
Under his leadership, BitMine will pivot from being purely a miner to an Ethereum-focused treasury company, adopting ETH as its primary reserve asset.
To kick off the transition, BitMine has announced a $250 million private placement, which will be used to accumulate Ether while maintaining its existing Bitcoin mining operations.
Lee stressed Ethereum's vital role in powering the stablecoin ecosystem, calling stablecoins the &#8220;ChatGPT of crypto&#8221; due to their rapid and widespread adoption. 
By holding ETH, Lee believes BitMine can help support and benefit from the infrastructure underpinning stablecoins.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46175268/ethereum-traders-target-4000-in-summer-whats-fueling-the-optimism">Ethereum Traders Target $4,000 In Summer: What&#8217;s Fueling The Optimism?</a>
Why It Matters: BitMine will begin tracking ETH-per-share as its principal performance metric, emulating how Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) uses BTC-per-share to communicate shareholder value. 
The firm plans to grow this figure via Ethereum price appreciation, reinvested cash flows, and strategic capital market activities.
This marks a shift in corporate treasury strategies, with a growing number of firms now exploring Ether and Solana-based reserves. Companies like SharpLink Gaming and DeFi Development have already started integrating ETH into their treasuries.
Just last week, <a href="https://www.benzinga.com/crypto/25/06/46089976/tom-lee-says-microstrategy-could-outpace-bitcoin-gains-goes-up-a-lot-more-as-btc-rallies">Lee praised MicroStrategy's model</a>, noting its ability to outperform Bitcoin through clever capital deployment, including the issuance of convertible debt at near-zero interest rates to acquire more BTC. 
He believes BitMine can replicate that success, but with Ethereum at its core.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46139888/michael-saylor-says-bitcoin-treasury-companies-can-unlock-even-more-growth-heres-how">Michael Saylor Says Bitcoin Treasury Companies Can Unlock Even More Growth: Here&#8217;s How</a></li>
</ul>

$ETH

BMNR

MSTR

Inside Tom Lee's Plan To Build 'MicroStrategy Of Ethereum' At BitMine

Last week, CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) said one of its large dialysis organization (LDO) customers has started ordering, with implementation planned for the second half of 2025.
The company said that implementation of its DefenCath catheter lock solution will initially target at least 50% more patients than previously planned, with an opportunity for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46048778/cormedix-inc-announces-customer-implementation" rel="noreferrer noopener">even further expansion</a>.
As a result, CorMedix made adjustments to its agreement with the customer and now expects a modest revenue increase in June with continued growth anticipated in the second half of the year.
The company updated its second-quarter net sales guidance from $31 million to a range of $35 million to $40 million to reflect the expected increased use of product by the customer.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46059139/cormedix-stock-hits-new-52-week-high-on-updated-guidance-the-details" rel="noreferrer noopener">CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details</a>
DefenCath is a catheter <a target="_blank" href="https://www.defencath.com/" rel="noreferrer noopener">lock</a> solution to reduce the risk of catheter-related bloodstream infections (CRBSIs) in adults with kidney failure undergoing chronic hemodialysis via a central venous catheter. The FDA approved the product in 2023.
HC Wainwright initiated coverage on CorMedix, citing &#8220;good things are worth the wait&#8230;&#8221;
Analyst Brandon Folkes wrote, &#8220;We believe DefenCath&#8217;s strong launch to date is indicative of good results these operators are seeing in practice, and in our view, this real world experience, along with the more formal real-world study DefenCath in undertaking is likely to support a more durable DefenCath long term revenue stream in CRBSIs than is currently reflected.&#8221;
HC Wainwright initiated with a Buy rating, <a target="_blank" href="https://www.benzinga.com/quote/CRMD/analyst-ratings" rel="noreferrer noopener">with a price forecast of $20</a>.
The company is in the initial t-year of the Transitional Drug Add-on Payment Adjustment (TDAPA) period and will enjoy a further three years post this initial reimbursement period, albeit at a lower level. The analyst sees potential for further outperformance in CorMedix stock.
Folkes added, &#8220;As we see longer-term revenue expectations come closer together and remove the uncertainty and wide variation, we believe CRMD investors could be further rewarded.&#8221;
On Friday, CorMedix priced its previously announced underwritten public offering of 6.6 million, with gross proceeds expected to be<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46136775/cormedix-inc-announces-pricing-of-public-offering-of-common-stock" rel="noreferrer noopener"> approximately $85 million</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/management/25/06/46166087/mark-cuban-slams-insurers-over-high-deductibles-urges-josh-hawley-to-change-the-game-with-two-part-plan" target="_blank" rel="noreferrer noopener">Mark Cuban Slams Insurers Over High Deductibles, Urges Josh Hawley To &#8216;Change The Game&#8217; With Two-Part Plan</a></li>
</ul>
Photo: MacroEcon via Shutterstock.

CRMD

CorMedix Analyst Says Investors Could Be Further Rewarded

<a href="https://truthsocial.com/@realDonaldTrump/114773696636727417">https://truthsocial.com/@realDonaldTrump/114773696636727417</a>

President Trump Posts On Truth Social "I apologize for the long wait on the Faith Leaders Conference Call. AT&T ought to get its act together. Please pass along the word to the tens of thousands of people who are there. We may have to reschedule the call, but we'll use another carrier the next time. AT&T obviously doesn't know what they're doing!"

New Fortress Energy shares are trading higher after the company announced it signed an LNG supply contract extension with Puerto Rico's government.

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/topic/nvidia" target="_blank" rel="noreferrer noopener">stock surged 44%</a> in the previous three months while the PHLX Semiconductor Sector Index (SOX), which Nvidia is part of, gained 29.41% during the period.
The stock is currently trading near its 52-week high of $158.71.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46149318/microsofts-next-gen-ai-chip-still-lags-nvidias-blackwell-postpones-launch" target="_blank" rel="noreferrer noopener">Microsoft&#8217;s Next-Gen AI Chip Still Lags Nvidia&#8217;s Blackwell, Postpones Launch</a>
In May, Nvidia reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong" rel="noreferrer noopener">first-quarter revenue</a> growth of 69% to $44.1 billion, topping the Street consensus estimate of $43.2 billion. The revenue increased by 12% sequentially.
Adjusted EPS of 96 cents topped the analyst consensus estimate of 88 cents.
Nvidia faced an export ban on H20 products to China on April 9. The company said it incurred a $4.5 billion charge in the first quarter related to H20 excess inventory and purchase obligations.&nbsp;
Nvidia forecasted second-quarter revenue of $45 billion, plus or minus 2%, versus&nbsp;estimates of $45.78 billion. The company noted its outlook reflects a loss of approximately $8 billion in H20 revenue due to the export control limitations.
Multiple Wall Street firms <a target="_blank" href="https://www.benzinga.com/quote/NVDA/analyst-ratings" rel="noreferrer noopener">raised their price targets</a> on the company after the results.
Nvidia has a consensus price target of&nbsp;$178.46&nbsp;based on the ratings of&nbsp;38&nbsp;analysts. The high is&nbsp;$250,&nbsp;issued by&nbsp;Loop Capital&nbsp;on&nbsp;June 25, 2025.&nbsp;
Nvidia made at least one acquisition during the quarter. As of June 27, Nvidia acquired&nbsp;Canadian AI startup, CentML, <a href="https://www.benzinga.com/m-a/25/06/46149909/nvidia-ai-acquisition" target="_blank" rel="noreferrer noopener">for undisclosed terms</a>.&nbsp;
CentML specializes in&nbsp;optimizing AI, offering innovative solutions that significantly enhance efficiency and performance.
The chip designer tapped CentML CEO Gennady Pekhimenko as a senior director for AI software at Nvidia.
CentML plans to optimize both model training and inference by running models after they&#8217;ve been trained.
Graphics processing units (GPUs) are also heavily used in inference today, and Pekhimenko noted them as a potential avenue of growth for the company.
Wedbush&#8217;s Dan Ives&nbsp;indicated&nbsp;that Nvidia is on a path to a <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45668727/nvidia-stock-is-surging-thursday-whats-fueling-the-move" target="_blank" rel="noreferrer noopener">$4 trillion market cap</a>, eventually reaching $5 trillion, backed by increasing AI spending.&nbsp;
Deepwater&#8217;s Gene Munster&nbsp;highlighted Nvidia&#8217;s core business&#8217;s impressive growth when excluding the impacts of the China chip restrictions.
Bank of America analyst&nbsp;Vivek Arya&nbsp;estimated that Nvidia&nbsp;holds 80%-85%&nbsp;of the total market for AI data center chips. The Blackwell platform prompted Arya to raise his earnings forecast for the calendar year 2027 to $7.23 per share, which is up 12%. He had projected long-term earnings power of $10 per share, driven by the company's AI hardware moat.
NVDA Price Action:&nbsp;NVDA stock is down slightly at $157.65 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46125295/google-future-wall-street-ai-hype-meets-skepticism" target="_blank" rel="noreferrer noopener">Google Future Divides Wall Street As AI Hype Meets Skepticism</a></li>
</ul>
Photo: Shutterstock

Tech

NVDA

What Is Going On With Nvidia Stock?

<a href="https://truthsocial.com/@realDonaldTrump/114773668772907430">https://truthsocial.com/@realDonaldTrump/114773668772907430</a>

President Trump Posts On Truth Social "I'm doing a major Conference Call with Faith Leaders from all over the Country, and AT&T is totally unable to make their equipment work properly. This is the second time it's happened. If the Boss of AT&T, whoever that may be, could get involved — It would be good. There are tens of thousands of people on the line!"

Press Releases

Outset Medical to Present at the 45th Annual TD Cowen Health Care Conference

Outset Medical Announces One-for-Fifteen Reverse Stock Split

Legal

Alert to Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra LifeSciences Holdings Corporation (NASDAQ: IART); Outset Medical, Inc. (NASDAQ: OM); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Is Investigating Claims on Your Behalf

Outset Medical to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

OUTSET MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Outset Medical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Outset Medical

Outset Medical (OM) オプション

Outset Medical (NASDAQ:OM) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル